MSLN and ovarian carcinoma: Top ranked tumor entities, such as ovarian carcinomas, endometrium carcinomas, pancreatic adenocarcinomas, and malignant mesothelioma, thus, may be the best candidates for therapy with drugs targeting MSLN.